This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Neurology 1996;46:9-11
The prototype case of the syndrome now designated as Rasmussen's encephalitis was identified in 1941 in a 7-year-old boy who developed right-sided seizures and subsequently slight right arm weakness; a left cortical biopsy revealed encephalitis. [1] By 1945 he had progressed to moderate right hemiparesis. A larger cortical resection again indicated inflammation. Seizures continued and right hemiplegia and hemianopia evolved. A left hemispherectomy was performed in 1956; sparse perivascular inflammation and glial nodules were found. Dr. Wilder Penfield, consulting in this case, raised the issues which continue to be debated to the present day. Is the encephalitic process the primary abnormality or a secondary response to the recurrent seizures? Why should an encephalitic process be unilateral? Can recurrent seizures lead to tissue destruction? Dr. Penfield, skeptical of the postulate that the syndrome was a primary inflammatory disorder, offered a new hat to anyone who proved him wrong.
The clinicopathologic syndrome of childhood-adolescent onset of unilateral seizure disorder with progressive hemiplegia consequent to focal cortical inflammation and tissue destruction has now been recognized and described worldwide. The complete spectrum of the syndrome in terms of age of onset, rate of evolution, topographic distribution of pathology, natural course, and response to therapy continues to be debated. In the series of 48 cases from the Montreal Neurological Hospital reviewed by Oguni et al, [2] the mean age of disease onset was 7 years (range, 1-15 yr), one patient was aged 30 years. The series included cases that stabilized spontaneously and at least one case that improved; these observations create a dilemma in evaluating open-label therapy claims. Neuroimaging done serially on patients demonstrates progressive tissue destruction, but to date this measure has not been included in therapeutic outcome assessments. Pathologic studies of cases with serial samples collected from repeated surgery and …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg